Apellis Pharmaceuticals said on Thursday the European drug regulator's advisory panel may decline to back an authorization for its drug to treat a chronic eye disease, sending its shares down more than 14% in premarket trading.
The company said it was informed on Wednesday that the panel may vote against the drug, a form of pegcetacoplan directly injected in the back of the eye, at the next meeting on Jan. 22-25.
The company has applied for use of the drug in patients with geographic atrophy, an advanced form of a disease that leads to degeneration of a part of the eye called macula.
The disease affects more than 2.5 million people in Europe, according to the company
https://finance.yahoo.com/news/1-apellis-says-eu-regulator-122851512.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.